Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Welcome to the TNL Beta! We are actively improving this experience.

Share Feedback

Source study found

Story checked

Anti-PEG antibodies drive contrasting liposome skin toxicity across species (opens in a new tab)

news-medical.net · 2026-11-05

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Every claim we could check holds up. Two of seven claims match the study. This overall rating is based only on the claims we could check. Five claims the study doesn't address.

  • 2 supported
  • 5 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not coveredThe authors investigated how anti-PEG antibodies alter liposome transport and skin toxicity across species, using antibody-stimulated and control mice and rats along with liposome tracking, immune-cell analysis, tissue imaging, pharmacokinetic modeling, and toxicity assessments.View evidenceHide evidence

Why this verdict

The abstract supports an interspecies in vivo mouse/rat comparison with anti-PEG antibody presence versus absence, biodistribution/skin accumulation, clearance/distribution dynamics, complement-related mechanism, and toxicity assessment. However, the abstract profile does not verify the more detailed method list, including liposome tracking, immune-cell analysis, tissue imaging, pharmacokinetic modeling, or the exact experimental structure.

1

Study evidence

Presence of anti-PEG antibodies in mice was associated with increased extravascular transport of stealth liposomes into skin, leading to higher skin accumulation and increased cutaneous toxicity.

“Strikingly, mice exhibited increased skin accumulation and toxicity in the presence of anti-PEG antibody”
2

Study evidence

Presence of anti-PEG antibodies reduced cutaneous exposure of stealth liposomes in rats due to predominant hepatic–splenic clearance.

“whereas rats showed reduced cutaneous exposure due to predominant hepatic-splenic clearance”
Claim 2 of 7Not coveredAnti-PEG IgM antibodies enhanced uptake of stealth liposomes by neutrophils, which the article describes as cells capable of carrying particles from the circulation into skin.View evidenceHide evidence

Why this verdict

The abstract profile supports the general mechanism that neutrophil phagocytosis/extravascular transport into skin depends on complement-mediated opsonization and that anti-PEG antibodies may alter this process. It does not verify the specific antibody class as IgM or provide assay-level evidence that anti-PEG IgM enhanced neutrophil uptake.

1

Study evidence

In mice, anti-PEG antibodies associated with increased complement-dependent neutrophil-mediated extravascular transport of stealth liposome into skin, leading to higher cutaneous accumulation and toxicity.

“which depended on the complement-mediated opsonization”
Claim 3 of 7Not coveredIn mice, limited complement activity allowed antibody-bound liposomes to remain available for neutrophil-mediated skin delivery, increasing cutaneous accumulation and worsening skin toxicity after liposomal doxorubicin administration.View evidenceHide evidence

Why this verdict

The mouse outcome—higher skin accumulation and increased cutaneous toxicity in the presence of anti-PEG antibodies—is supported at abstract level. But the story's unhedged causal mechanism, especially that limited complement activity allowed antibody-bound liposomes to remain available for neutrophil-mediated skin delivery, is more specific than the abstract profile verifies.

1

Study evidence

Presence of anti-PEG antibodies in mice was associated with increased extravascular transport of stealth liposomes into skin, leading to higher skin accumulation and increased cutaneous toxicity.

“Strikingly, mice exhibited increased skin accumulation and toxicity in the presence of anti-PEG antibody”
2

Study evidence

In mice, anti-PEG antibodies associated with increased complement-dependent neutrophil-mediated extravascular transport of stealth liposome into skin, leading to higher cutaneous accumulation and toxicity.

“which depended on the complement-mediated opsonization”
Claim 4 of 7Not coveredIn rats, stronger complement activation and uptake by macrophages in the liver and spleen accelerated systemic clearance, reducing the amount of liposomes reaching the skin.View evidenceHide evidence

Why this verdict

The abstract profile supports reduced rat cutaneous exposure attributed to predominant hepatic-splenic clearance and links the species contrast to complement-related mechanisms. It does not verify the detailed causal chain that rats had stronger complement activation, macrophage uptake in liver and spleen, and accelerated systemic clearance as directly demonstrated steps.

1

Study evidence

Presence of anti-PEG antibodies reduced cutaneous exposure of stealth liposomes in rats due to predominant hepatic–splenic clearance.

“whereas rats showed reduced cutaneous exposure due to predominant hepatic-splenic clearance”
2

Study evidence

In mice, anti-PEG antibodies associated with increased complement-dependent neutrophil-mediated extravascular transport of stealth liposome into skin, leading to higher cutaneous accumulation and toxicity.

“which depended on the complement-mediated opsonization”
Claim 5 of 7Not coveredThe researchers' plasma-skin model supported competing contributions of transport into skin, local clearance, and elimination from the circulation, and the article says changing antibody levels affected the magnitude of the response but did not explain the opposing species patterns.View evidenceHide evidence

Why this verdict

The abstract profile mentions distribution dynamics and spatial accumulation patterns, but it does not describe a plasma-skin model, competing model terms for transport/local clearance/systemic elimination, or experiments showing antibody concentration changed response magnitude without explaining opposing species patterns.

1

Study evidence

In mice, anti-PEG antibodies associated with increased complement-dependent neutrophil-mediated extravascular transport of stealth liposome into skin, leading to higher cutaneous accumulation and toxicity.

“which depended on the complement-mediated opsonization”
Claim 6 of 7SupportedThe article says a new publication in Acta Pharmaceutica Sinica B discusses how anti-polyethylene glycol antibodies affect the movement of stealth liposomes from blood into skin, revealing contrasting distribution and toxicity patterns in mice and rats.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the headline-level scientific framing: the paper evaluates anti-PEG antibodies' effects on extravascular transport/skin accumulation of stealth liposomes and reports contrasting mouse versus rat outcomes, including increased mouse skin accumulation/toxicity and reduced rat cutaneous exposure via hepatic-splenic clearance.

1

Study evidence

Presence of anti-PEG antibodies in mice was associated with increased extravascular transport of stealth liposomes into skin, leading to higher skin accumulation and increased cutaneous toxicity.

“Strikingly, mice exhibited increased skin accumulation and toxicity in the presence of anti-PEG antibody”
2

Study evidence

Presence of anti-PEG antibodies reduced cutaneous exposure of stealth liposomes in rats due to predominant hepatic–splenic clearance.

“whereas rats showed reduced cutaneous exposure due to predominant hepatic-splenic clearance”
Claim 7 of 7SupportedThe story says the findings provide a mechanistic basis for considering immune-system differences when selecting animal models and interpreting preclinical skin-toxicity results, and that further clinical investigation is needed to determine relevance to patients.View evidenceHide evidence

Why this verdict

The abstract profile supports the broader, hedged interpretation that interspecies physiological/immunological variability affects stealth-liposome fate and may inform prediction or mitigation of liposomal toxicities in translational settings. The story's statement that further clinical investigation is needed is a cautious translational caveat and does not overstate patient relevance.

1

Study evidence

Presence of anti-PEG antibodies in mice was associated with increased extravascular transport of stealth liposomes into skin, leading to higher skin accumulation and increased cutaneous toxicity.

“Strikingly, mice exhibited increased skin accumulation and toxicity in the presence of anti-PEG antibody”
2

Study evidence

Presence of anti-PEG antibodies reduced cutaneous exposure of stealth liposomes in rats due to predominant hepatic–splenic clearance.

“whereas rats showed reduced cutaneous exposure due to predominant hepatic-splenic clearance”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper presents a mechanistic interpretation involving complement-mediated opsonization and species-specific distribution dynamics, but the abstract does not provide assay details proving each mechanistic step.

    The story presents detailed causal mechanisms involving complement strength, neutrophil carriage, macrophage uptake, and systemic clearance, but its caveats do not acknowledge that the abstract-level evidence lacks assay-level detail for these steps.

    From in_vivo_animal

  • The abstract does not report quantitative effect sizes, sample sizes, time points, dosing regimens, or statistical analyses for the mouse or rat findings.

    The story does not mention the absence of quantitative/statistical details at abstract depth, which limits independent assessment of magnitude and robustness.

    From in_vivo_animal study (rodent comparative biodistribution/toxicity); in vivo rat biodistribution assessment

4 things the story did carry across
  • The paper's primary aim was to determine how anti-PEG antibodies affect extravascular transport, skin accumulation, and cutaneous toxicity of stealth liposomes in vivo.
  • In mice, anti-PEG antibodies were associated with increased skin accumulation and increased cutaneous toxicity of sLip/DOX.
  • In rats, anti-PEG antibodies were associated with reduced cutaneous exposure, attributed in the abstract to predominant hepatic-splenic clearance.
  • Species-specific divergence is central: mouse results may not generalize to rats, and interspecies variability complicates preclinical prediction of liposomal toxicity.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDetermine how anti-PEG antibodies affect extravascular transport, skin accumulation, and cutaneous toxicity of stealth liposomes in vivo.in vivo animal study (rodent comparative biodistribution/toxicity)Expand

In plain English

In mice, the presence of anti-PEG antibodies was associated with increased extravascular transport of stealth liposomes (sLip) into skin, resulting in higher cutaneous accumulation and increased skin toxicity compared with absence of anti-PEG antibodies, as reported in the paper abstract.

Key findings

  • Presence of anti-PEG antibodies in mice was associated with increased extravascular transport of stealth liposomes into skin, leading to higher skin accumulation and increased cutaneous toxicity.
“Strikingly, mice exhibited increased skin accumulation and toxicity in the presence of anti-PEG antibody”
What this piece can’t prove
  • Abstract does not report experimental details such as dosing regimen, sample sizes, time points, quantification methods, or statistical analyses.
  • Species-specific differences are reported but the abstract does not provide methodological detail on how cross-species comparisons were controlled or standardized.

2 further details could not be confirmed from the summary.

2in vivo animalExplain the interspecies differences (mouse vs rat) in anti-PEG–driven changes in liposome fate via differential complement activation and organ (hepatic–splenic vs cutaneous) distribution dynamics.in vivo rat biodistribution assessmentExpand

In plain English

In rats, presence of anti-PEG antibodies was associated with reduced cutaneous exposure of stealth liposomes; the authors attribute this to predominant hepatic–splenic clearance rather than neutrophil-mediated extravascular transport to skin, implicating anti-PEG–driven complement activation in shifting organ distribution toward liver and spleen.

Key findings

  • Presence of anti-PEG antibodies reduced cutaneous exposure of stealth liposomes in rats due to predominant hepatic–splenic clearance.
“whereas rats showed reduced cutaneous exposure due to predominant hepatic-splenic clearance”
What this piece can’t prove
  • Unclear whether rat experiments included direct measures of complement activation, temporal kinetics, or comparison metrics that would support the causal link between anti-PEG antibodies and hepatic–splenic clearance.

1 further detail could not be confirmed from the summary.

3in vivo animalExplain the interspecies differences (mouse vs rat) in anti-PEG–driven changes in liposome fate via differential complement activation and organ (hepatic–splenic vs cutaneous) distribution dynamics.in vivo animalExpand

In plain English

The study reports that anti-PEG antibodies alter the in vivo fate of stealth liposomes via complement-dependent opsonization, producing divergent outcomes in mouse versus rat: in mice anti-PEG antibodies are associated with increased complement-driven neutrophil-mediated extravascular transport into skin with higher cutaneous accumulation and toxicity, whereas in rats anti-PEG presence is associated with reduced cutaneous exposure owing to predominant hepatic–splenic clearance.

Key findings

  • In mice, anti-PEG antibodies associated with increased complement-dependent neutrophil-mediated extravascular transport of stealth liposome into skin, leading to higher cutaneous accumulation and toxicity.
  • In rats, anti-PEG antibodies associated with reduced cutaneous exposure of stealth liposome due to predominant hepatic–splenic clearance.
“which depended on the complement-mediated opsonization”
What this piece can’t prove
  • Unclear whether complement activation/opsonization was directly measured or inferred from distribution/toxicity outcomes; assay details and temporal dynamics are not provided.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 21 candidate papers

Candidate

Author correction to “Human carboxylesterases: a comprehensive review” [Acta Pharmaceutica Sinica B 8 (2018) 699-712]

Acta Pharmaceutica Sinica B · 2026 · Crossref

Source (opens in a new tab)
Candidate

Author correction to “The crucial function of IDO1 in pulmonary fibrosis: from the perspective of mitochondrial fusion in lung fibroblasts and targeted molecular inhibition” [Acta Pharmaceutica Sinica B 15 (2025) 3125–3148]

Acta Pharmaceutica Sinica B · 2026 · Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 15 more candidates considered.